J Leg Med. 2020 Jul-Dec;40(3-4):355-368. doi: 10.1080/01947648.2020.1868941.
After a decade of fits and starts in regulating commercial tobacco products, the U.S. Food and Drug Administration (FDA) has built the infrastructure needed for robust tobacco product regulation. This article lays out a vision for the FDA in its second decade of tobacco product regulation. To realize the promise of the Family Smoking Prevention and Tobacco Control Act, the FDA must move quickly to adopt high-impact tobacco product regulation, define and operationalize the public health standard in a way that advances health equity, and bring all of its authority and resources to bear to reduce health disparities. In addition, the agency must engage more productively with states to reduce and eliminate tobacco use.
经过十年在规范商业烟草制品方面的断断续续努力，美国食品和药物管理局（FDA）已经建立了进行强有力烟草产品监管所需的基础设施。本文为 FDA 在第二个十年的烟草产品监管工作勾勒出了一个愿景。为了实现《家庭吸烟预防和烟草控制法案》的承诺，FDA 必须迅速采取行动，通过具有高度影响力的烟草产品监管措施，以促进健康公平的方式来定义和实施公共卫生标准，并利用其所有权力和资源来减少健康差异。此外，该机构还必须更有效地与各州合作，以减少和消除烟草使用。
